Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.92 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3975460 | 0.98 | HTR6 (0.88) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| Bromide SCHEMBL6316273 | 0.98 | HTR6 (0.88) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL29855108 | 0.96 | HTR6 (0.85) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL65291 | 0.96 | HTR6 (1.00) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL3522066 | 0.96 | HTR6 (1.00) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL1190916 | 0.96 | HTR6 (1.00) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL8501091 | 0.94 | HTR6 (0.96) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL8503565 | 0.94 | HTR6 (0.96) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| Hydrochloric Acid SCHEMBL20522843 | 0.94 | HTR6 (0.96) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL8502194 | 0.94 | HTR6 (0.96) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050112066-A1 | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity | CONCAT LP, A CALIFORNIA LIMITED PARTNERSHIP (US) | 2005-05-26 | — | — | US | disclosed |
| US-6881732-B2 | Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements | CHELATOR LLC (US) | 2005-04-19 | — | — | US | disclosed |
| US-20040006055-A1 | Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements | CONCAT, LTD. A CALIFORNIA LIMITED PARTNERSHIP (US) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006055-A1 | Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements | SOD1, SLC39A11, SLC40A1 | HTR6 1943/4885HPGD 275/4885KMT2A 2919/4885 |
| US-20050112066-A1 | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity | SLC39A14, CHIA, CA2 | HTR6 4862/4885HPGD 2037/4885KMT2A 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.